Israeli firm begins 2nd trial of coronavirus antibody drug

An Israeli company has begun its second trial of a coronavirus antibody drug, after a promising first trial.

The drug, manufactured from antibodies found in the plasma of recovered coronavirus patients and produced by the Kamada pharmaceutical firm, has been administered to 70 patients, according to Zman Yisrael, the Times of Israel’s sister site.

 

Most Popular
If you’d like to comment, join
The Times of Israel Community.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.